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infection, and the burden of asymptomatic cryptococcaemia remains unknown. We conducted a prospective study at a large public hospital in India to determine whether such a screening strategy should be considered amongst Indian patients with advanced HIV disease.
methods

Study design
We prospectively enrolled inpatient and outpatient HIV-infected adults >18 years of age who had CD4 cells <100 cells/mm 3 that were seen at Sassoon Hospital and Byramjee Jeejeebhoy Government Medical College (BGJMC), Pune, India between January 2011 and January 2012. BGJMC is a public, teaching tertiary care facility that contains one of India's largest ART centres with over 30,000 patients registered since 2004. The study was approved by the Byramjee Jeejeebhoy Medical College Research Ethics Committee, Pune, India and the Johns Hopkins University Institutional Review Board, Baltimore, USA.
All adult patients >18 years of age from inpatient wards and those visiting the outpatient ART centre with a documented CD4 count <100 cells/mm 3 were eligible to enrol in the study. A trained clinician examined each patient for overt clinical symptoms or signs of cryptococcal meningitis that would exclude them from the study. After consenting, participants were tested for CrAg by latex agglutination assay (Meridian Bioscience Inc., USA).
Asymptomatic cryptococcal antigenaemia was defined as the presence of positive CrAg with dilution at >1:2. Baseline demographic and clinical information such as the date of HIV diagnosis and history of ART were collected. The most recent CD4 count was extracted from the patient's medical records at the time of enrolment. Phone follow-ups were conducted at 3 and 6 months after study entry to collect any new history of hospitalisation or death.
Participants with positive CrAg underwent cerebrospinal fluid examination to rule out cryptococcal meningitis. All CrAg-positive patients also underwent skin examination, chest radiography and abdominal ultrasound to rule out cryptococcal disease other than meningitis. At the time of the study, the standard of care for asymptomatic cryptococcaemia was careful observation; therefore, only those with confirmed meningitis were admitted to the hospital for further management. The primary study outcome was the presence of asymptomatic cryptococcal antigenaemia. The secondary outcomes were a diagnosis of incidental cryptococcal meningitis and 6-month all-cause mortality.
Statistical analysis
Data were analysed using Stata version 13.0 (StataCorp, College Town, Texas, USA). Continuous variables were compared across groups using Mann-Whitney (Rank-sum) test, and categorical variables were compared using Fisher's exact test. Logistic regression was used to analyse the risk factors of mortality at the 95% confidence level.
Results
A total of 208 patients were enrolled, of which 28 (13%) were inpatients. The median age of participants was 40 years (interquartile range [IQR]: 35-49) and 134 (65%) were male. The median CD4 cell count was 64.5 cells/µL (IQR, 37-82) and 81 (40%) had CD4 cell count <50 cells/mm 3 . Only 38 (18%) participants were on ART at the time of entry. There was no clinical suspicion of meningitis in any of the participants when CrAg testing was performed. At baseline, 16 (8%; 95% confidence interval [CI], 4%-12%) had a positive CrAg assay result. Of those, eight (53%) occurred in persons with a CD4 count <50 cells/mm 3 . CrAg was positive in 1 (3%) of 38 patients on ART compared to 15 (9%) of 170 ART-naïve participants (P = 0.32). Five (18%) inpatients had positive CrAg. Median CD4 count did not differ significantly between CrAg-positive and CrAg-negative persons (P = 0.32). Of 16 persons with a positive CrAg, three had CrAg titres of 1:2048, three had 1:1024, two had 1:62 and one each had titres of 1:256, 1:128, 1:32 and 1:8 and the remaining had CrAg titres above 1:2 and below 1:8. Upon further investigation, three (19%) CrAg-positive participants had incidental cryptococcal meningitis and had titres of 1:128, 1:1024 and 1:2048, respectively. All were treated with intravenous amphotericin. The rest did not show any evidence of cryptococcal disease upon further investigation by skin examination, chest radiography and abdominal ultrasound. As shown in Table 1 , there were no significant differences in gender, median age and Amongst the 142 participants whose vital status could be ascertained at 6 months, 40 (19%) had died. Mortality was reported in 6 (38%) CrAg-positive participants compared with 34 (17%) CrAg-negative participants (P = 0.06). Mortality was reported in 18 (22%) of the 81 participants with CD4 counts <50 cells/mm 3 . All CrAg-positive participants who died were ART-naïve when CrAg testing was performed. CrAg-positive participants had a 2.79 times greater risk of 6-month mortality (95% CI, 0.95-8.19, P = 0.06) [ Table 2 ]. In multivariate analysis, after adjustment for CD4 cell count, age, sex and ART status, the odds ratio for cryptococcal antigenaemia-related mortality at 6 months was 3.18 (95% CI, 0.60-16.88, P = 0.17).
discussion
We found an 8% prevalence of cryptococcal antigenaemia in HIV-infected adults with a CD4 count <100 cells/mL in Pune, India. Moreover, confirmed cryptococcal meningitis was found in nearly one-fifth of those with cryptococcal antigenaemia. A high 6-month all-cause fatality rate was also observed amongst those with cryptococcal antigenaemia. To the best of our knowledge, this is the first study from India assessing the burden of cryptococcal antigenaemia in advanced HIV-infected patients without symptoms of cryptococcal disease.
Consistent with our study, studies from resource-limited settings from Asia and Africa have also reported the prevalence of cryptococcal antigenaemia ranging between 2% (Vietnam) and 21% (Cambodia and Nigeria). [11] [12] [13] [14] [15] A study from the USA showed cryptococcal antigenaemia prevalent in 2.9% (CI = 2.2%-3.7%) of ART-naïve, advanced HIV patients. [16] Furthermore, our study observed a relatively low prevalence of cryptococcal antigenaemia amongst those on ART compared to ART-naïve participants. These findings are consistent with previous studies suggesting that ART may be protective against cryptococcaemia. [17] Cryptococcal antigenaemia is reported to be a strong predictor of mortality in ART-naïve, advanced HIV-infected patients across all types (high resource and resource limited) of settings. [13, 16, 18] In multivariate analysis, cryptococcal antigenaemia was associated with a 3.5-fold greater risk of all-cause mortality which is clinically significant though it did not reach statistical significance at the 95% confidence level. Our study did not investigate what portion of the mortality was related to cryptococcal disease. Tuberculosis is the leading cause for early mortality amongst advanced HIV-infected patients, and since India has the world's largest burden of TB, we cannot assume that cryptococcal disease was the primary cause of death in all our study participants. [19] Nonetheless, cryptococcal-related deaths can be prevented by CrAg screening at entry to care, as majority of deaths due to cryptococcal disease occur within a few months of first seeking HIV care. [7] [8] [9] India is estimated to have the world's third largest burden of HIV, and over 35% of them enter HIV care with CD4 counts <200 cells/mm 3 . [3, 20] Thus, a routine CrAg screening strategy as part of India's National AIDS Control programme may help to avert significant morbidity and mortality. The cost efficiency of such a programme is likely to be great, due to the high burden of cryptococcal antigenaemia in India, as demonstrated by earlier studies. [21, 22] Our study has some limitations. First, we could not ascertain the causes of death amongst all those who were followed up to 6 months. Second, we were only able to track two-thirds of our advanced HIV patients by phone, and the outcomes of the remaining one-third could not be verified. Finally, we may have missed subtle clinical signs and symptoms for mild cryptococcal meningitis at baseline despite the clinician's use of a standardised checklist. Despite these limitations, our study is the first in India to confirm the significance of screening advanced HIV patients for asymptomatic cryptococcal antigenaemia, as recommended by the WHO.
conclusions
The high prevalence of cryptococcal antigenaemia and associated all-cause mortality amongst ART-naïve patients with CD4 count <100 cells/cumm without a history of cryptococcal disease may signify the importance of targeted, routine CrAg screening in India. With the advent of a rapid, low-cost urine test for CrAg, this would be especially important to consider for India's National HIV programme.
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